8-K: Verona Pharma Reports Strong Ohtuvayre Launch with $42.3 Million in 2024 Sales; Advances Pipeline

Verona Pharma announces positive Q4 and full-year 2024 results, driven by the successful launch of Ohtuvayre and progress in its Phase 2 clinical programs.

Summary

• Verona Pharma reported net product sales of $36.6 million in Q4 2024 and $42.3 million for the full year, driven by the launch of Ohtuvayre.
• More prescriptions were filled through February 2025 than in Q4 2024, with over 4,600 unique prescribers, including approximately 55% of Tier 1 HCPs.
• The company is advancing Phase 2 programs in bronchiectasis and a fixed-dose combination in COPD, with a Phase 2b trial planned for the second half of 2025.
• Nuance Pharma, Verona's development partner in Greater China, received approval for Ohtuvayre in Macau and expects Phase 3 trial results in China in mid-2025.
• Cash and cash equivalents at the end of 2024 were $399.8 million.
• The net loss for the year was $173.4 million, compared to $54.4 million in 2023, primarily due to increased R&D and SG&A expenses related to the Ohtuvayre launch and clinical trials.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with a successful product launch, clinical trial progress, and a strong cash position. However, increased expenses and net losses temper the overall sentiment.

Positives

• Successful launch of Ohtuvayre with significant initial sales and prescriber adoption.
• Progress in Phase 2 clinical trials for bronchiectasis and fixed-dose combination COPD treatment.
• Regulatory approval of Ohtuvayre in Macau by development partner Nuance Pharma.
• Strong cash position of $399.8 million at the end of 2024.
• Ohtuvayre added to the 2025 GOLD report COPD treatment algorithm.

Negatives

• Net loss increased significantly to $173.4 million for the year ended December 31, 2024, compared to $54.4 million in 2023.
• Increased SG&A expenses due to commercialization efforts for Ohtuvayre.
• Increased R&D expenses due to ongoing Phase 2 clinical trials.

Risks

• Reliance on the success of Ohtuvayre, their only commercial product.
• Potential for adverse side effects associated with Ohtuvayre.
• Dependence on third-party manufacturers and suppliers.
• Risk of lawsuits related to patents covering Ohtuvayre.
• The terms of the credit agreement and the revenue interest purchase and sale agreement place restrictions on operating and financial flexibility.

Future Outlook

Verona Pharma will continue to build on the successful commercialization of Ohtuvayre in the US, progress Phase 2 programs, and initiate regulatory activities in the EU and UK for potential marketing authorization applications. Nuance Pharma is expected to report results from its pivotal Phase 3 trial in China in mid-2025.

Management Comments

• 2024 was another transformational year for Verona Pharma with the US approval and launch of Ohtuvayre (ensifentrine), the first novel inhaled therapy available for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in over 20 years, said David Zaccardelli, Pharm. D., President and Chief Executive Officer.
• We are very pleased to report the extremely strong start to the launch continues to build momentum with more prescriptions dispensed through February 2025 than in the entire fourth quarter of 2024.

Industry Context

Verona Pharma's Ohtuvayre is positioned as a novel inhaled therapy for COPD, a market with significant unmet needs. The company is competing with established treatments and other emerging therapies in the respiratory disease space.

Comparison to Industry Standards

• Ohtuvayre's launch is being closely watched in comparison to other recent COPD drug launches, such as Trelegy Ellipta by GSK and Innoviva, to assess its market penetration and adoption rate.
• The Phase 2 programs in bronchiectasis and fixed-dose combinations are aimed at expanding the potential market for ensifentrine, similar to how companies like Boehringer Ingelheim have diversified their respiratory portfolios.
• Nuance Pharma's efforts in China mirror the strategies of other multinational pharmaceutical companies seeking to tap into the growing Chinese market for respiratory therapies.

Stakeholder Impact

• Shareholders: Positive impact due to successful product launch and clinical progress, but concerns about increased net losses.
• Employees: Positive impact due to company growth and expansion of commercial operations.
• Customers (Patients): Potential for improved COPD treatment options with Ohtuvayre.
• Suppliers: Increased demand for manufacturing and supply of Ohtuvayre.
• Creditors: Stable financial position due to strong cash reserves.

Next Steps

• Initiate a Phase 2b clinical trial for a fixed-dose combination of ensifentrine and glycopyrrolate in the second half of 2025.
• Continue enrolling subjects in a Phase 2 trial for nebulized ensifentrine in patients with bronchiectasis.
• Progress regulatory activities for potential marketing authorization application submissions for Ohtuvayre in the European Union and the UK.
• Await results from Nuance Pharma's pivotal Phase 3 trial in China in mid-2025.

Key Dates